Skip to main content

Proqr Therapeutics(PRQR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.7300
Day High1.8500
Open:1.7300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Proqr Therapeutics

Select a category then submit the form to load news
Tipranks
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
Tipranks
Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)
Tipranks
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Tipranks
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY)
Tipranks
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
ProQR (PRQR) Receives a Buy from Evercore ISI
Tipranks
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR)
Tipranks
ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
Tipranks
Citizens JMP Sticks to Their Buy Rating for ProQR (PRQR)
Tipranks
ProQR Therapeutics Advances RNA Therapy Pipeline
Tipranks
Evercore ISI Sticks to Their Buy Rating for ProQR (PRQR)
Tipranks
ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs
Tipranks
Cantor Fitzgerald Reaffirms Their Buy Rating on ProQR (PRQR)
Tipranks
Citizens JMP Reaffirms Their Buy Rating on ProQR (PRQR)
Tipranks
Cantor Fitzgerald Remains a Buy on ProQR (PRQR)
Tipranks
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)
Motley Fool
Why Shares of ProQR Therapeutics Dropped on Wednesday
PR Newswire
Lilly and ProQR to Expand RNA Editing Collaboration
Globe Newswire
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
Globe Newswire
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
Globe Newswire
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
Globe Newswire
ProQR Announces First Quarter 2022 Operating and Financial Results
Globe Newswire
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
Globe Newswire
ProQR to Participate in the Kempen Life Sciences Conference
Globe Newswire
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
Globe Newswire
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
Globe Newswire
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

Profile

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.